AU2012245002A1 - Weight loss composition - Google Patents
Weight loss composition Download PDFInfo
- Publication number
- AU2012245002A1 AU2012245002A1 AU2012245002A AU2012245002A AU2012245002A1 AU 2012245002 A1 AU2012245002 A1 AU 2012245002A1 AU 2012245002 A AU2012245002 A AU 2012245002A AU 2012245002 A AU2012245002 A AU 2012245002A AU 2012245002 A1 AU2012245002 A1 AU 2012245002A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- vitamin
- composition according
- probiotic microorganisms
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 151
- 230000004580 weight loss Effects 0.000 title claims description 22
- 239000006041 probiotic Substances 0.000 claims abstract description 41
- 235000018291 probiotics Nutrition 0.000 claims abstract description 41
- 244000005700 microbiome Species 0.000 claims abstract description 39
- 230000000529 probiotic effect Effects 0.000 claims abstract description 39
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 32
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 27
- 230000001737 promoting effect Effects 0.000 claims abstract description 23
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 24
- 229930003448 Vitamin K Natural products 0.000 claims description 22
- 235000019168 vitamin K Nutrition 0.000 claims description 22
- 239000011712 vitamin K Substances 0.000 claims description 22
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 22
- 229940046010 vitamin k Drugs 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 16
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 15
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 15
- 239000000811 xylitol Substances 0.000 claims description 15
- 235000010447 xylitol Nutrition 0.000 claims description 15
- 229960002675 xylitol Drugs 0.000 claims description 15
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 15
- 239000004365 Protease Substances 0.000 claims description 14
- 235000013361 beverage Nutrition 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 11
- 102000007544 Whey Proteins Human genes 0.000 claims description 9
- 108010046377 Whey Proteins Proteins 0.000 claims description 9
- 235000021119 whey protein Nutrition 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 8
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 7
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 210000000987 immune system Anatomy 0.000 claims description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 235000019419 proteases Nutrition 0.000 claims description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 claims description 5
- 239000007894 caplet Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 5
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 235000019143 vitamin K2 Nutrition 0.000 claims description 5
- 239000011728 vitamin K2 Substances 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- 108010004032 Bromelains Proteins 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 4
- 229920001100 Polydextrose Polymers 0.000 claims description 4
- 235000019835 bromelain Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 235000019834 papain Nutrition 0.000 claims description 4
- 229940055729 papain Drugs 0.000 claims description 4
- 239000001259 polydextrose Substances 0.000 claims description 4
- 235000013856 polydextrose Nutrition 0.000 claims description 4
- 229940035035 polydextrose Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 235000019156 vitamin B Nutrition 0.000 claims description 3
- 239000011720 vitamin B Substances 0.000 claims description 3
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims description 2
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- 235000019175 phylloquinone Nutrition 0.000 claims description 2
- 239000011772 phylloquinone Substances 0.000 claims description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims description 2
- 229960001898 phytomenadione Drugs 0.000 claims description 2
- 230000036541 health Effects 0.000 description 14
- 206010033307 Overweight Diseases 0.000 description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000007140 dysbiosis Effects 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 235000005282 vitamin D3 Nutrition 0.000 description 6
- 239000011647 vitamin D3 Substances 0.000 description 6
- 229940021056 vitamin d3 Drugs 0.000 description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 5
- 208000027244 Dysbiosis Diseases 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 5
- 235000013406 prebiotics Nutrition 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229960003975 potassium Drugs 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 229940010250 vitamin k 2 Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- 102000008192 Lactoglobulins Human genes 0.000 description 3
- 108010060630 Lactoglobulins Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 108010067454 caseinomacropeptide Proteins 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 235000021241 α-lactalbumin Nutrition 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241001027872 Lactobacillus acidophilus La-14 Species 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000021407 appetite control Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- -1 but not limited to Proteins 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013410 fast food Nutrition 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229940042126 oral powder Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241001328122 Bacillus clausii Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000289619 Macropodidae Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000012791 bagels Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940046374 chromium picolinate Drugs 0.000 description 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 235000014168 granola/muesli bars Nutrition 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 229940066544 lactobacillus sporogenes Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013384 milk substitute Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 230000005804 musculo-skeletal problem Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020262 oat milk Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/34—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present disclosure relates generally to the use of compositions comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol and uses thereof for promoting weight and/or fat loss in a subject.
Description
WO 2012/142678 PCT/AU2012/000427 Weight loss composition Technical Field The present disclosure relates generally to the use of compositions comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol and uses thereof for promoting weight and/or fat loss in a subject. Background of the Disclosure The number of overweight and obese individuals has more than doubled over the past two decades. The health problems and consequences associated with overweight and obese individuals are many and varied, including type 2 diabetes, gall bladder disease, hypertension, dyslipidaemia, insulin resistance, musculoskeletal problems, cardiovascular disease, atherosclerosis, some cancers, sleep apnoea, breathlessness, asthma, social isolation/depression and daytime sleepiness/fatigue. Such health problems cause discomfort and pain and decrease the quality of life to the individual and are a costly clinical problem. Many studies that have shown that there is a clear relationship between overweight and obese individuals and increased mortality. Treatment of overweight or obese individuals includes diet and exercise regimes. Unfortunately not all individuals are able to diet and/or exercise effectively due to factors such as sedentary lifestyles, the ready availability of fast foods and convenience foods leading to poor dietary selection, lack of free time, stress and depression. As a result many individuals are unable to reduce their weight and/or maintain a healthy weight. Some individuals choose to undergo surgery in an attempt to lose weight, for example by undergoing surgery to reduce the size of the stomach or the length of the bowels. Unfortunately, complications from surgery are common and the individual is required to modify their behaviour towards food to enhance the likelihood of a successful outcome. Even individuals who are not categorised as overweight or obese may desire improved physical performance and appearance resulting from decreased weight and/or fat. Accordingly, there is a need for a composition that promotes weight loss and/or fat loss in an individual.
WO 2012/142678 PCT/AU2012/000427 2 The present inventors have found that a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol promotes weight loss and/or fat loss in an individual. Summary According to a first aspect of the present disclosure there is provided a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol. According to a second aspect of the present disclosure there is provided a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol for promoting weight loss and/or fat loss in a subject. In one embodiment the composition according to the first or second aspect may further comprise vitamin K. Typically, the one or more probiotic microorganisms comprises Lactobacillus and/or Bifidobacterium. In one embodiment the probiotic microorganisms comprise Lactobacillus acidophilus. In another embodiment the probiotic microorganisms comprise Bifidobacterium lactis, In yet another embodiment the probiotic microorganisms comprises Lactobacillus acidophilus and Bifidobacterium lactis. The probiotic microorganisms in the composition may be in an amount of from about 1 billion to about 50 billion IU/mg. In one embodiment the probiotic microorganisms in the composition are in an amount of about 3 billion IU/mg. The glutamine in the composition may be in an amount of from about 50 to about 600 IU/mg. In one embodiment the glutamine in the composition is in an amount of about 250 IU/mg. In one embodiment the at least one sugar alcohol is xylitol, mannitol or sorbitol, In particular embodiments the at least one sugar alcohol is xylitol. The xylitol in the composition may be in an amount of from about 10 to about 300 g/kg. In one embodiment the xylitol in the composition is in an amount of about 110 g/kg. In some embodiments the composition further comprises vitamin K. The vitamin K may be vitamin K1 and/or vitamin K2. The vitamin K in the composition may be in an amount of from about WO 2012/142678 PCT/AU2012/000427 3 0.1 pg/mg to about 100 pg/mg. In one embodiment the vitamin K in the composition is in an amount of about 1 pg /mg. In another embodiment the composition further comprises vitamin D. In another embodiment the composition further comprises whey protein. In another embodiment the composition further comprises vitamin B. In another embodiment the composition further comprises polydextrose. In another embodiment the composition further comprises at least one medium chain triglyceride. In another embodiment the composition further comprises one or more enzyme. The enzyme may be selected from the group consisting of protease, bromelain and papain. Typically the composition is in a form suitable for oral administration. In particular embodiments the composition is in the form of a liquid, a powder or a unit dosage form such as a tablet, capsule or caplet. According to a third aspect of the present disclosure there is provided a method of promoting weight loss and/or fat loss in a subject, the method comprising administering to the subject a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol. The composition is typically administered to the subject orally. In one embodiment the composition is in the form of a liquid, a powder or a unit dosage form. The unit dosage form may be a tablet, a capsule or a caplet. Typically between 1 and 5 unit dosage forms are administered per day. According to a fourth aspect of the present disclosure there is provided a method of promoting a healthy immune system in a subject, the method comprising administering to the subject a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol.
WO 2012/142678 PCT/AU2012/000427 4 The composition is typically administered to the subject orally. In one embodiment the composition is in the form of a liquid, a powder or a unit dosage form. The unit dosage form may be a tablet, a capsule or a caplet. Typically between 1 and 5 unit dosage forms are administered per day. In some embodiments the oral composition as defined above may be in the form of a food stuff or beverage, or suitable for administering with a food stuff or beverage. According to a fifth aspect of the present disclosure there is provided a use of a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol in the manufacture of a medicament for promoting weight loss and/or fat loss in a subject. According to a sixth aspect of the present disclosure there is provided a use of a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol in the manufacture of a medicament for promoting a healthy immune system in a subject. Definitions Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. In the context of this specification, the terms "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element. In the context of this specification, the term "about," is understood to refer to a range of numbers that a person of skill in the art would consider equivalent to the recited value in the context of achieving the same function or result. In the context of this specification, the term "sugar alcohol" or "sugar alcohols" is understood to refer to those compounds with the general formula H(HCHO)o.
1 H and which can be administered to a subject. A person skilled in the art will appreciate that the term does not include the sugar alcohol glycol.
WO 2012/142678 PCT/AU2012/000427 5 In the context of this specification, the term "probiotic microorganisms" is to be given its broadest construction and is understood to refer to any live microorganisms which when administered in an effective amount promotes a health benefit. In the context of this specification, the term "prebiotic" is to be given its broadest construction and is understood to refer to any non-digestible substance that stimulates the growth and/or activity of bacteria, in particular probiotic bacteria, in the digestive system. In the context of this specification, the terms "promote" and "promoting" and variations thereof as used herein refer to the ability of a composition of the present disclosure to achieve or assist in achieving a benefit, either directly or indirectly, in relation to weight loss and/or fat loss, the health of the gastrointestinal tract, the health of the immune system and/or diseases associated therewith; or to improve the ability to achieve or assist in achieving a measurable benefit, either directly or indirectly, in relation to weight loss and/or fat loss, the health of the gastrointestinal tract, the health of the immune system and/or diseases associated therewith; or otherwise prevent, hinder, retard, or reverse the deterioration in the health of a subject in any way whatsoever. Thus the terms "promote", "promoting" and the like are to be considered in their broadest context. In the context of this specification, the term "derivative" or "derivatives" is understood to include compounds that are formed from a parent compound by chemical reaction(s). For example a derivative of vitamin D 3 is a compound formed by a chemical reaction with vitamin D 3 . In the context of this specification, the term "precursor" or precursors" is understood to refer to a compound that forms a parent compound by chemical reaction(s) or metabolic process(es). For example a precursor of vitamin D3 forms vitamin D3 via chemical reaction(s) or metabolic process(es). In the context of this specification, "food", "foods", "beverage" or "beverages" includes but is not limited to health foods, functional foods and foods for specified health use. When such food or beverage of the present disclosure is used for subjects other than humans, the term can be used to include a feedstuff.
WO 2012/142678 PCT/AU2012/000427 6 In the context of this specification, the term "subject" includes humans, primates, livestock animals (eg. sheep, pigs, cattle, horses, donkeys), laboratory test animals (eg. mice, rabbits, rats, guinea pigs), companion animals (eg. dogs, cats) and captive wild animals (eg. foxes, kangaroos, deer). Typically, the subject is a human or a laboratory test animal. Even more typically, the subject is a human. Detailed Description Embodiments of the present disclosure provide compositions comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol. The compositions promote weight loss and/or fat loss in a subject. The compositions may be used as meal replacements or alternatively in addition to meals as part of a calorie controlled diet/weight loss regime. The compositions of the disclosure are also useful for managing diseases and/or disorders that are associated with excessive calorie intake, such as obesity, metabolic syndrome and diseases and conditions related thereto. In some embodiments the compositions may promote a healthy immune system thereby reducing the risk of autoimmune disease, reducing inflammation, and promoting the health of the gastrointestinal tract thereby promoting healthy digestion and absorption of nutrients in a subject. In some embodiments the compositions may promote an improved mood state and/or boost the metabolism and assist in balancing the appetite of a subject. In other embodiments the compositions may promote the health of a subject by reducing the risk of hypothyroidism. The compositions of the present disclosure may also assist in reducing or inhibiting bone decay in a subject, thereby decreasing the pain associated with the effects of carrying extra weight. Currently available weight loss and fat loss products seek to address the issue of weight loss and fat loss by simply reducing the calorie intake of a subject or by or increasing the loss of calories in a subject. The deficiency of the currently available products is that they do not address the overall health of the subject or address the health issues associated with overweight or obese individuals.
WO 2012/142678 PCT/AU2012/000427 7 The compositions of the present disclosure seek to not only address the issue of weight loss and or fat loss but also to reduce systematic inflammation and stress in the gastrointestinal tract thereby promoting an improvement in the health of the gastrointestinal tract, promoting weight loss and/or fat loss and promoting additional health benefits. Compositions comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol work synergistically promoting bacterial growth in the gut because the glutamine and at least one sugar alcohol nourish the probiotic microorganisms during proliferation. According to the World Health Organisation Global Database on Body Mass Index (BMI), in 2011 the current classification for BMI indicates that, the term "overweight" refers a subject having a BMI of between 25 and 29.9 and the term "obese" refers to a subject having a body mass index of greater than 30. Whilst not wishing to be bound by theory, it is suggested that overweight and obese individuals may experience systemic inflammation due to the release of pro-inflammatory signals by fat cells. Systemic inflammation is a major problem in overweight and obese individuals and can result in insulin resistance which leads to type 2 diabetes; and in leptin resistance which can lead to poor appetite control due to a decreased feeling of satiety and suppressed metabolism. Systemic inflammation can also cause oestrogen-dominant conditions, joint pain, cardiovascular disease, adrenal fatigue, depression and gastrointestinal problems. In accordance with embodiments of the present disclosure the compositions may reduce systemic inflammation and promote the health of the gastrointestinal tract and therefore assist in preventing and/or promoting the improvement of conditions associated with systemic inflammation. Overweight and obese individuals may also have increased risk of dysbiosis (or dysbacteriosis) which is a condition that causes microbial imbalances on or within the body. Dysbiosis can cause major problems in the gastrointestinal tract or on the skin, and has been associated with inflammatory bowel disease, chronic fatigue syndrome, poor oestrogen clearance and compromised digestion which can reduce the absorption of nutrients. Dysbiosis can also lead to leaky gut and can comprise vitamin K in a subject. The probiotic microorganisms in accordance with embodiments of the present disclosure may reduce dysbiosis thereby promoting absorption of B vitamins and vitamin K.
WO 2012/142678 PCT/AU2012/000427 8 The compositions of the present disclosure may comprise any one or more probiotic microorganisms. The one or more probiotic microorganisms may be present in the composition as specially selected strains as a culture concentrate or as part of a multiple strain blend with a variety of excipients. The one or more probiotic microorganisms may include but are not limited to one or more of a strain of Lactobacillus, Bifidobacterium, Streptococcus Saccharomyces, Bacillus, Enterococcus, Bacteroides or Propionibacterium The Lactobacillus may be one or more of, but is not limited to, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Lactobacillus salivarius, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus reuteri, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus gasseri or Lactobacillus sporogenes. In one embodiment the Lactobacillus is Lactobacillus acidophilus. The Bifidobacterium may be one or more of, but is not limited to, Bifidobacterium animals, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium Lafti, Bifidobacterium breve or Bifidobacterium lactis. In one embodiment the Bifidobacterium is Bifidobacterium lactis. The Streptococcus may be one or more of, but is not limited to, Streptococcus thermophilus, Streptococcus faecium, or Streptococcus salivarius. The Saccharomyces may be one or more of, but is not limited to, Saccharomyces cerevisiae or Saccharomyces boulardii. The Bacillus may be one or more of, but is not limited to, Bacillus coagulans, Bacillus cereus, Bacillus clausii, or Bacillus pumilus. The Enterococcus may be, but is not limited to, Enterococcus faecium. In accordance with particular embodiments of the present disclosure the amount of one or more probiotic microorganisms present in the compositions may be between about 1 billion to about 100 billion IU/mg, or more typically between about 2 billion to about 5 billion IU/mg. Alternatively, the WO 2012/142678 PCT/AU2012/000427 9 composition may comprise about 2.5 billion IU/mg, 3.0 billion IU/mg, 3.5 billion IU/mg, 4.0 billion IU/mg or 4.5 billion IU/mg of the one or more probiotic microorganisms. The glutamine may be present in the composition in the form of a salt or derivative. In accordance with particular embodiments the amount of glutamine present in the composition may be between about 1 IU/mg and about 1000 IU/mg, or more typically between about 50 lU/mg and about 600 IU/mg. Alternatively, the composition may comprise about 100 IU/mg, 150 IU/mg, 200 IU/mg, 250 IU/mg, 300 IU/mg, 350 IU/mg, 400 IU/mg, 450 IU/mg, 500 IU/mg or 550 of glutamine. The compositions of the present disclosure comprise at least one sugar alcohol. The at least one sugar alcohol is typically selected from a sugar alcohol that also functions as a sweetener. The at least one sugar alcohol may include, but is not limited to, one or more of glycerol, erythritol, xylitol, mannitol, sorbitol, isomalt, maltitol, lactitol or polyglycitol. In one embodiment the at least one sugar alcohol is sorbitol. In another embodiment the at least one sugar alcohol is mannitol. In yet another embodiment the at least one sugar alcohol is xylitol. When present, the xylitol may be present in the composition in the form of a salt or derivative. In accordance with particular embodiments the amount of xylitol present in the composition may be between about 1 g/kg and about 1000 g/kg, or more typically between about 10 g/kg and about 300 g/kg. Alternatively, the composition may comprise about 20 g/kg, 30 g/kg, 40 g/kg, 50 g/kg, 60g/kg, 70g/kg, 80g/kg, 90g/kg, 100g/kg, 110g/kg, 120g/kg, 130g/kg, 140g/kg, 150g/kg, 160 g/kg, 170 g/kg, 180 g/kg, 190 g/kg, 200 g/kg, 210 g/kg, 220 g/kg, 230 g/kg, 240 g/kg, 250 g/kg, 260 g/kg, 270 g/kg, 280 g/kg or 290 g/kg of xylitol. In some embodiments the composition may further comprise vitamin K. The vitamin K may be vitamin Ki and/or vitamin K 2 . Typically the vitamin K is vitamin K2. Those skilled in the art will appreciate that the vitamin K may be present in the form of suitable precursors, derivatives or analogues thereof. The body does not store vitamin K and therefore it is an essential vitamin that needs to be continuously ingested. Vitamin K2 is produced by probiotics and some vegetables such as broccoli, however vitamin K2 produced by probiotics is not always readily absorbed in the gut and the harmful bacteria in the gut does not permit vegetables to be digested effectively enough to extract sufficient vitamin K 2 from such foods. As well are producing vitamin K, the one or more probiotic microorganisms in the compositions of the present disclosure harmonise the gut of an WO 2012/142678 PCT/AU2012/000427 10 overweight or obese individual thereby allowing vitamin K to be more effectively extracted from food. Whilst not wishing to be bound by theory the inventors of the subject application believe that the combination of one or more probiotic microorganisms and vitamin K (in particular vitamin K 2 ) in the compositions promote the proliferation of the beneficial bacteria and promote the absorption of vitamin K 2 . In accordance with particular embodiments of the present disclosure the amount of vitamin K present in the composition may be between about 0.1 pg/mg and about 100 pg/mg, or more typically between about 0.2 p/mg and about 5 p/mg w/w. Alternatively, the composition may comprise about 0.4 pg/mg, 0.6 pg/mg, 0.8 pg/mg, 1.0 pg/mg, 1.2 pg/mg, 1.4 pg/mg, 1.6 pg/mg, 1.8 pg/mg, 2.0 pg/mg, 2.2 pg/mg, 2.4 pg/mg, 2.6 pg/mg, 2.8 pg/mg, 3.0 pg/mg, 3.2 pg/mg, 3.4 pg/mg, 3.6 pg/mg, 3.8 pg/mg, 4.0 pg/mg, 4.2 pg/mg, 4.4 pg/mg, 4.6 pg/mg or 4.8 pg/mg of vitamin K. Fat cells can sequester vitamin D3 which can result in overweight and obese individuals suffering from vitamin D3 deficient related conditions, for example low bone density, inflammation, autoimmune diseases, poor immunity to colds and flu, depression, and cancer. Accordingly, in some embodiments vitamin D is added to the compositions to assist in replacing the vitamin D sequestered by fat cells. The vitamin D may be present as vitamin D2 and/or D 3 . In some embodiments the compositions comprise vitamin D3 (cholecalciferol). However, a person skilled in the art will appreciate that the vitamin D3 may be in the form of any suitable precursor, derivative or analogue thereof. In some embodiments the composition comprises vitamin D 2 (ergocalciferol), or metabolites, analogues or derivatives thereof. In some embodiments the compositions may further comprise a fibre and/or a prebiotic. In some embodiments the compositions further comprise polydextrose which acts both as a source of a fibre and a prebiotic. In other embodiments the fibre and prebiotic may be inulin, fructooligosaccharides (FOS), xylooligosaccharides (XOS) and/or galactooligosaccharides (GOS). Those skilled in the art will appreciate that other sources of fibre and/or prebiotics may be added to the compositions. In some embodiments of the present disclosure at least one enzyme, such as but not limited to, protease (peptidase), bromelain and papain and/or at least one medium chain triglyceride (medium chain (6 to 12 carbons) fatty acid esters of glycerol) may be added to the compositions. The at least WO 2012/142678 PCT/AU2012/000427 11 one medium chain triglyceride may be selected from the group consisting of caproic acid (C6), caprylic acid (C8), capric acid (C10) and lauric acid (C12). Whilst not wishing to be bound by theory, in overweight or obese individuals medium chain triglycerides are not always effectively utilised as such individuals often have a deficiency of stomach acid or pancreatic enzymes. Accordingly, a combination of at least one medium chain triglyceride and at least one enzyme in the compositions of the invention promotes the digestion of the at least medium chain triglyceride and ensures that the medium chain triglyceride is effectively utilised as energy thereby further promoting weight loss and/or fat loss. In yet further embodiments the compositions may comprise protein. The protein may be whey protein, however a person skilled in the art will appreciate that other protein sources may also be used. The whey protein may be in the form of a concentrate, an isolate, and/or a hydrolysate. The whey protein is typically obtained from cow's milk, however those skilled in the art will appreciate that whey protein sourced from other milk may be used. The whey protein may comprise at least one of alpha lactalbumin, beta lactoglobulin, bovine serum albumin immunoglobulins and glycomacropeptides or mixtures thereof. The compositions of the present disclosure may further comprise vitamins and/or minerals and/or amino acids. The vitamins and/or minerals may be one or more vitamins or minerals indicated for weight loss and/or appetite control. The vitamins and minerals may be selected from, but not limited to: vitamins A, B1, B2, B 3 , B 5 , B 6 , 89, B12, C, D, E and calcium, chromium, copper, fluorine, iodine, iron, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, sodium and zinc. The amino acids may be selected from, but are not limited to: alanine, arginine, aspartic acid, cystine, glycine, histidine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan and tyrosine. The compositions may be used as meal replacements or supplements. Alternatively, the compositions may form part of a calorie controlled diet. The methods and compositions of the disclosure may form part of a weight management program in a subject in need thereof. The compositions may be taken before, during, or after a meal and/or in between meals where necessary.. In some embodiments the serving size of the composition may be between about 1 g and about 100 g, or between about 5 g and about 50 g, or between about 25 g and about 35 g, or about 26 g, 27 g, 28 g, 29 g, 30 g, 31 g, 32 g, 33 g or 34 g. Those skilled in the art will however WO 2012/142678 PCT/AU2012/000427 12 appreciate that the exact amounts and rates of administration of the compositions will depend on a number of factors such as the particular composition being administered, the age, body weight, general health, sex and dietary requirements of the subject, as well as any drugs or agents used in combination or coincidental with the compositions. Based on the teaching herein those skilled in the art will, by routine trial and experimentation, be capable of determining suitable dosage regimes on a case-by-case basis. The compositions may be provided to the user, for example, in a liquid form, a powder form or as a solid unit dosage form such as a tablet, capsule or caplet. The compositions may be added in powder form by the user to any type of drink or food product (for example water, fruit juice or yoghurt) and consumed there after. In another embodiment, the compositions may simply be consumed as a powder in the absence of a drink or additional food product. In yet another embodiment the composition may be conveniently presented and consumed in a dosage form prepared by any of the methods well known in the art. The method may include the step of bringing the components of the oral composition into association with a carrier which constitutes one or more accessory ingredients. In general, oral compositions are prepared by uniformly and intimately bringing into association the components of the composition with a liquid carrier or finely divided solid carrier, or both and then, if necessary, shaping the product into the desired composition. The present disclosure also contemplates that the composition may be conveniently incorporated in a variety of food and/or beverage products, nutraceutical products, pharmaceuticals and over-the counter formulations. The food may be a solid form such as a powder, or a liquid form. Specific examples of the types of beverages or foods include, but are not limited to water-based, milk-based, yoghurt-based, other dairy-based, milk-substitute based such as soy milk or oat milk, or juice-based beverages, water, soft drinks, carbonated drinks, and nutritional beverages, (including a concentrated stock solution of a beverage and a dry powder for preparation of such a beverage); baked products such as crackers, breads, muffins, rolls, bagels, biscuits, cereals, bars such as muesli bars, health food bars and the like, dressings, sauces, custards, yoghurts, puddings, pre packaged frozen meals, soups and confectioneries. The compositions of the disclosure may be used in conjunction with other treatments directed to WO 2012/142678 PCT/AU2012/000427 13 other diseases. As such, the compositions of the invention may be used as part of a treatment regime or combination therapy, wherein the role of the composition is to promote weight loss and/or fat loss. For example, the composition may be administered to a subject undergoing drug treatment for heart disease, wherein the composition assists in weight loss and/or fat loss. The reference in this specification to any prior publication (or information derived from it), or to -any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates. The present disclosure will now be described with reference to the following specific examples, which should not be construed as in any way limiting the scope of the invention.
WO 2012/142678 PCT/AU2012/000427 14 Examples Example I - Oral powder composition By way of example only a suitable oral composition for use in accordance with the disclosure is outlined below. The following is to be construed as merely an illustrative example of a composition and not as a limitation of-the scope of the present disclosure in any way. A typical powder composition for oral administration is prepared by combining the following components: Lactobacillus acidophilus LA 14 0.469 g/Kg (150 billion per gram) Bifidobacterium lactis BI-04 0.052 g/Kg (450 billion per gram) Glutamine 7.813 g/Kg Xylitol 101.563 g/Kg Vitamin K 0.156 g/Kg (optional) Whey protein isolate 15.625 g/Kg Whey protein concentrate 562.50 g/Kg Enzyme blend 3.125 g/Kg (protease (peptidase), bromelain, protease 6.0, protease 4.5, papain) Medium chain triglyceride powder 54.688 g/Kg (alpha lactalbumin, beta lactoglobulin, bovine serum albumin, immunoglobulins (IgG) and glycomacropeptides) Polydextrose (Litesse) 101.563 g/Kg Vitamin A 0.060 g/Kg Vitamin B 1 (as thiamine hydrochloride) 0.017 g/Kg Vitamin B2 (as riboflavin) 0.027 g/Kg Vitamin B3 (as nicotinamide) 0.156 g/Kg Vitamin B6 (as pyridoxine hydrochloride) 0.030 g/Kg Vitamin B7 (as biotin) 0.047 g/Kg Vitamin B9 (as folic acid) 0.031 g/Kg Vitamin B 1 2 0.003 g/Kg Vitamin C (ascorbic acid) 0.625 g/Kg Vitamin D 3 0.016 g/Kg WO 2012/142678 PCT/AU2012/000427 15 Vitamin E (d-alpha tocopheryl succinate) 0.189 g/Kg Calcium d-pantothenate 0.027 g/Kg Calcium carbonate 21.094 g/Kg Zinc (zinc oxide) 0.233 g/Kg Copper (cupric sulphate pentahydrate) 0.046 g/Kg Iron (ferrous fumarate) 0.570 g/Kg Manganese (manganese sulphate monohydrate) 0.120 g/Kg Potassium (potassium iodide 1%) 0.154 g/Kg Selenium (selenomethionine 1.25%) 0.031 g/Kg Magnesium (magnesium oxide heavy) 12.555 g/Kg Potassium (potassium citrate) 9.256 g/Kg Chromium (Chromium Picolinate 2%) 0.318 g/Kg Xanthan Gum 5.469 g/Kg Vanilla Flavour 12.350 g/Kg Cream Flavour 13.547 g/Kg Maltodextrin 75.634 g/Kg In particular exemplary compositions the dosage is 32 g of the resulting powder (typically dissolved in 200 mL water or other liquid) to be taken once to three times daily.
WO 2012/142678 PCT/AU2012/000427 16 Example 2 - Oral powder composition An exemplary oral composition in accordance with the present disclosure comprises: PER SERVE (32g) PER 100g Unit Unit Energy 468.906 kJ 1465.332 kJ Protein 15.158 g 47.369 g Carbohydrates Total 7.517 g 23.491 g Sugars 1.488 g 4.651 g Lactose 0.779 g 2.434 g Unavailable 3.250 g 10.156 g Xylitol 3.250 g 10.156 g Dietary Fibre 3.065 g 9.578 g Fat Total 2.537 g 7.929 g Saturated 0.800 g 2.500 g Litesse . 3.250 g 10.156 g Vitamin A 625.000 IU 1953.125 IU Retinol Equivalent 187.500 mcg 585.938 mcg Vitamin D3 50.000 IU 156.250 IU Cholecalciferol 1.250 mcg 3.906 mcg Folic Acid 100.000 mcg 312.500 mcg Thiamine Hydrochloride 0.550 mg 1.179 mg Riboflavin 0.850 mg 2.656 mg Nicotinamide 5.000 mg 15.625 mg Pyridoxine Hydrochloride 0.973 mg 3.040 mg Equivalent to Pyridoxine 0.800 mg 2.500 mg Vitamin B12 (Cyanocobalamin) 1.000 mcg 3.125 mcg Biotin 15.000 mcg 46.875 mcg Pantothenic Acid (Vitamin B5) 0.800 mg 2.500 mg WO 2012/142678 PCT/AU2012/000427 17 Ascorbic Acid 20.000 mg 62.500 mg Vitamin E 5.000 mg 15.625 mg Zinc 6.000 mg 18.750 mg Copper 375.000 mcg 1171.875 mcg Iron 6.000 mg 18.750 mg Manganese 1.250 mg 3.906 mg Iodine 37.500 mcg 117.188 mcg Selenium 12.500 mcg 39.063 mcg Magnesium 229.596 mg 717.487 mg Calcium 341.172 mg 1066.164 mg Sodium 45.168 mg 141,151 mg Potassium 231.405 mg 723.141 mg Chromium 25.000 mcg 78.125 mcg Glutamine 250.000 mg 781.250 mg NATURALLY OCCURING COMPONENTS Alpha lactalbumin 1941.000 mg 6065.625 mg Beta lactoglobulin 6820.000 mg 21256.250 mg Bovine Serum Albumin 236.000 mg 737.500 mg Immunoglobulins (IgG) 586.000 mg 1831.250 mg Glycomacropeptides 2792.000 mg 8725.000 mg Lactoferrin - 253.818 mg 793.182 mg Lactoperoxidase 93.067 mg 290.833 mg Isoleucine 1.143 g 3.570 g Leucine 2.179 g 6.809 g Lysine 1.876 g 5.861 g Methionine 0.390 g 1.217 g Phenylalanine 0.716 g 2.236 g Threonine 1.386 g 4.330 g Trytophan 0.386 g 1.205 g Valine 1.176 g 3.675 g WO 2012/142678 PCT/AU2012/000427 18 Histidine 0.374 g 1.169 g Alanine 1.064 g 3.323 g Arginine 0.532 g 1.663 g Aspartic Acid 2.032 g 6.350 g Cysteine/cystine 0.460 g 1.438 g Glutamic Acid 3.487 g 10.895 g Glycine 0.467 g 1.458 g Proline 1.221 g 3.814 g Serine 0.978 g 3.056 g Tyrosine 0.631 g 1.970 g Lactobacillus acidophilus LA 14 2,250,000,000 per mg Bifidobacterium lactis'BI-04 750,000,000 per mg
Claims (33)
1. A composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol.
2. A composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol for promoting weight loss and/or fat loss in a subject.
3. The composition according to claim 1 or claim 2, wherein the composition further comprises vitamin K.
4. The composition according to any one of claims 1 to 3, wherein the one or more probiotic microorganisms
5. The composition according to any one of claims 1 to 4, wherein the one or more probiotic microorganisms comprises Lactobacillus acidophilus.
6. The composition according to any one of claims 1 to 5, wherein the one or more probiotic microorganisms comprises Bifidobacterium lactis.
7. The composition according to any one of claims 1 to 6, wherein the one or more probiotic microorganisms in the composition is in an amount of from about 1 billion to about 50 billion IU/mg.
8. The composition according to any one of claims 1 to 7, wherein the one or more probiotic microorganisms in the composition is in an amount of about 3 billion IU/mg.
9. The composition according to any one of claim 1 to 8, wherein the glutamine in the composition is in an amount of from about 50 to about 600 IU/mg.
10. The composition according to any one of claim 1 to 9, wherein the glutamine in the composition is in an amount of about 250 IU/mg. WO 2012/142678 PCT/AU2012/000427 20
11. The composition according to any one of claim 1 to 10, wherein the at least one sugar alcohol is selected from the group consisting of xylitol, mannitol and sorbitol.
12. The composition according to any one of claims 1 to 11, wherein the at least one sugar alcohol is xylitol.
13. The composition of claim 11 or claim 12, wherein the xylitol is in an amount of from about 10 to about 300 g/kg.
14. The composition according to any one of claims 11 to 13, wherein the xylitol in the composition is in an amount of about 110 g/kg.
15. The composition according to any one of claims 3 to 14, wherein the vitamin K comprises vitamin K1 and/or vitamin K2.
16. The composition according to any one of claims 3 to 15, wherein the vitamin K in the composition is in an amount of from about 0.1 to about 100 p/mg.
17. The composition according to any one of claims 3 to 16, wherein the vitamin K in the composition is in an amount of about 1 p/mg.
18. The composition according to any one of claim 1 to 17, wherein the composition further comprises vitamin D.
19. The composition according to any one of claim 1 to 18, wherein the composition further comprises whey protein.
20. The composition according to any one of claim 1 to 19, wherein the composition further comprises vitamin B.
21. The composition according to any one of claim 1 to 20, wherein the composition further comprises polydextrose. WO 2012/142678 PCT/AU2012/000427 21
22. The composition according to any one of claim 1 to 21, wherein the composition further comprises at least one medium chain triglyceride.
23. The composition according to any one of claim 1 to 22, wherein the composition further comprises at least one enzyme.
24. The composition according to claim 23, wherein the at least one enzyme is selected from the group consisting of protease, bromelain and papain
25. A method of promoting weight loss and/or fat loss in a subject, the method comprising administering to the subject a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol.
26. A method of promoting a healthy immune system in a subject, the method comprising administering to the subject a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol.
27. The method according to claim 25 or claim 26, wherein the composition is administered to the subject orally.
28. The method according to any one of claims 25 to 27, wherein the composition is in the form of a powder or a unit dosage form.
29. The method according to claim 28, wherein the unit dosage form is a tablet, a capsule or a caplet.
30. The method according to claim 29, wherein between 1 and 5 unit dosage forms are administered per day.
31. The method according to any one of claims 30 to 29, wherein the oral composition is in the form of a food stuff or beverage.
32. Use of a composition comprising one or more probiotic microorganisms, glutamine and at least WO 2012/142678 PCT/AU2012/000427 22 one sugar alcohol in the manufacture of a medicament for promoting weight loss and/or fat loss in a subject.
33. Use of a composition comprising one or more probiotic microorganisms, glutamine and at least one sugar alcohol in the manufacture of a medicament for promoting a healthy immune system in a subject.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012245002A AU2012245002A1 (en) | 2011-04-21 | 2012-04-23 | Weight loss composition |
AU2014100089A AU2014100089A4 (en) | 2011-04-21 | 2014-01-31 | Weight loss composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011901524 | 2011-04-21 | ||
AU2011901524A AU2011901524A0 (en) | 2011-04-21 | Weight loss composition | |
AU2012245002A AU2012245002A1 (en) | 2011-04-21 | 2012-04-23 | Weight loss composition |
PCT/AU2012/000427 WO2012142678A1 (en) | 2011-04-21 | 2012-04-23 | Weight loss composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2014100089A Division AU2014100089A4 (en) | 2011-04-21 | 2014-01-31 | Weight loss composition |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2012245002A1 true AU2012245002A1 (en) | 2013-11-28 |
Family
ID=47040982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012245002A Abandoned AU2012245002A1 (en) | 2011-04-21 | 2012-04-23 | Weight loss composition |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2012245002A1 (en) |
WO (1) | WO2012142678A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2769736A1 (en) * | 2013-02-22 | 2014-08-27 | Bill, Anja | Pharmaceutical composition for the treatment of burnout syndrome |
DK3006027T3 (en) | 2014-10-08 | 2017-12-18 | Professional Dietetics Spa | Compositions comprising amino acids for use in the treatment of systemic inflammation associated with stroke in dysphagia patients |
BE1025428B1 (en) * | 2018-01-23 | 2019-02-14 | Omega Pharma Innovation & Development Nv | FOOD SUPPLEMENT AND USE THEREOF |
CN111449183A (en) * | 2019-06-24 | 2020-07-28 | 广州维汝堂营养健康咨询有限公司 | Probiotic solid beverage with fat reducing function |
CN111254087B (en) * | 2019-12-27 | 2021-12-17 | 杭州娃哈哈科技有限公司 | Lactobacillus helveticus with high adhesion performance and function of enhancing immunity and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4038800A (en) * | 1999-03-29 | 2000-10-16 | Nutrasweet Company, The | Nutraceuticals having |
US8524304B2 (en) * | 2005-11-23 | 2013-09-03 | The Coca-Cola Company | High-potency sweetener composition with probiotics/prebiotics and compositions sweetened therewith |
US20070134391A1 (en) * | 2005-11-23 | 2007-06-14 | The Coca-Cola Company | High-Potency Sweetener Composition for Treatment and/or Prevention of Autoimmune Disorders and Compositions Sweetened Therewith |
DE202006017823U1 (en) * | 2006-11-21 | 2007-02-15 | Ionescu, John G., Dr. | Dietic food with increased effect of free radical binder, useful, e.g. for the treatment of allergic condition disease, comprises a protein and a sugar |
-
2012
- 2012-04-23 AU AU2012245002A patent/AU2012245002A1/en not_active Abandoned
- 2012-04-23 WO PCT/AU2012/000427 patent/WO2012142678A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2012142678A1 (en) | 2012-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10471084B2 (en) | Composition and method for treating acute respiratory tract infections | |
EP2011506A1 (en) | Supplementation of maternal diet | |
EP1339294A1 (en) | Nutritional composition for an immune condition | |
WO2012089783A1 (en) | A nutritional composition comprising fiber and probiotics for reducing stress-related intestinal symptoms | |
AU2002221860A1 (en) | Nutritional composition for an immune condition | |
EP2945494B1 (en) | Baby food composition comprising viable propionic acid-producing bacteria and viable lactic acid-producing bacteria | |
US20130280225A1 (en) | Fiber and probiotics for reducing intestinal symptoms related to stress | |
JP2016520305A (en) | Association of Lactonospirae bacteria and body weight in gastrointestinal microbiota | |
WO2012089784A1 (en) | Fiber and probiotics for reducing intestinal symptoms related to chronic stress | |
JP2016505024A5 (en) | ||
AU2012245002A1 (en) | Weight loss composition | |
EP2165713A1 (en) | Whey and thymus function | |
AU2014100089A4 (en) | Weight loss composition | |
WO2023176952A1 (en) | Composition for controlling proliferation of bacterium in intestine, and use thereof | |
RU2801210C2 (en) | Composition in a powder form containing iron and probiotic bacteria | |
EP4059354A1 (en) | Synergistic combination of butyric-acid-producing prebiotics and probiotics | |
US20200229480A1 (en) | Nutritional compositions with partially hydrolysed proteins for use in inducing glucose and/or insulin response(s) close to the ones observed with human milk | |
Mc Donagh et al. | Milk and dairy products for better human health | |
Jortberg et al. | NUTRITION, MALNUTRITION, AND PROBIOTICS | |
McNally | Nutrition, Malnutrition, and Probiotics | |
Singh | DAIRY NUTRACEUTICALS AND FUNCTIONAL DAIRY FOODS: CURRENT STATUS, ISSUES AND CHALLENGES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |